Hypothesis

Combining intermittent senolytic dosing with a short‑acting NAD+ precursor given shortly before each senolytic pulse increases senescent cell apoptosis while allowing lower senolytic doses, thereby decreasing off‑target effects such as thrombocytopenia.

Mechanistic Rationale

Senescent cells exhibit a heightened reliance on anti‑apoptotic BCL‑2 family proteins for survival [[https://pmc.ncbi.nlm.nih.gov/articles/PMC12456441/]]. NAD+ replenishment activates SIRT1, which deacetylates p53 and FOXO transcription factors, shifting the balance toward pro‑apoptotic signaling [[https://doi.org/10.1038/s42003-020-01514-y]]. When NAD+ levels are elevated, the mitochondrial NAD+/NADH ratio improves, enhancing SIRT1‑mediated deacetylation of BCL‑2 antagonists and lowering the threshold for senolytic‑induced apoptosis. An intermittent "hit‑and‑run" senolytic schedule already shows efficacy without continuous exposure [[https://doi.org/10.7554/elife.75492]]. Aligning the NAD+ peak with senolytic exposure should synergistically sensitize senescent cells to apoptosis, permitting dose reduction.

Experimental Design

Animal study – Use 20‑month‑old C57BL/6 mice divided into four groups (n=15 per group):

1. Vehicle control.
2. Intermittent senolytic (dasatinib 5 mg/kg + quercetin 50 mg/kg) administered once weekly for three weeks.
3. NAD+ precursor (nicotinamide riboside, 300 mg/kg) given orally 2 hours before each senolytic dose (same schedule as group 2).
4. NAD+ precursor alone (same timing, no senolytic).

Endpoints – At 48 hours after the final senolytic dose:

• Quantify senescent cell burden in lung, liver, and adipose tissue via p16^INK4a immunofluorescence and SASP cytokine ELISA (IL‑6, MMP‑3).
• Measure circulating platelets to assess thrombocytopenia risk.
• Evaluate physical function using grip strength and frailty index.
• Assess mitochondrial respiration in isolated tissues (Seahorse XF).

Human ex‑vivo validation – Isolate mesenchymal stem cells from donors >65 years, induce senescence with irradiation, then treat with nicotinamide riboside (1 mM) for 4 hours followed by dasatinib+quercetin (10 nM+1 µM) for 24 hours. Compare apoptosis (caspase‑3/7 activity) and senescence‑associated β‑galactosidase to senolytic‑only and NAD+‑only conditions.

Predicted Outcomes

If the hypothesis is correct, group 3 will show:

• A ≥30 % greater reduction in p16^INK4a‑positive cells vs group 2 at the same senolytic dose.
• Equivalent or superior senescent cell clearance compared to group 2 despite a 50 % lower senolytic dose (tested in a separate dose‑reduction arm).
• No significant drop in platelet counts, whereas group 2 exhibits mild thrombocytopenia (>15 % decrease).
• Improved grip strength and lower frailty index relative to controls.
• In human MSCs, synergistic increase in apoptosis (>2‑fold over additive) only when NAD+ priming precedes senolytic exposure.

Potential Pitfalls and Falsification

Failure to observe enhanced senescent cell clearance or toxicity reduction in group 3 would falsify the hypothesis. Alternative outcomes—such as NAD+ alone reducing senescence without senolytics—would still inform mechanistic understanding but would not support the claimed synergy. Careful timing of NAD+ administration is critical; if the precursor is given too early or too late, the expected sensitization may not occur, which would also refute the specific mechanistic claim but not the broader concept of metabolic priming.

This proposal is directly testable, uses clinically relevant agents, and offers a clear path to lower‑dose senolytic regimens with improved safety profiles.